Evidence map›Paper›PMID 39648664›Full record

ArticleRenal failure2024

Tanshinone I improves renal fibrosis by promoting gluconeogenesis through upregulation of peroxisome proliferator-activated receptor-γ coactivator 1α.

Yanfang Bai, Hui Wen, Junyan Lin, Xinying Liu, Hua Yu, Ming Wu, Ling Wang, Dongping Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanfang BaiDepartment of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hui WenDepartment of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Junyan LinThe Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xinying LiuDepartment of Rheumatology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Hua YuShanghai Zhabei District Central Hospital, Shanghai, China.
Ming WuDepartment of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ling WangDepartment of Nephrology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Dongping ChenDepartment of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal fibrosis, a hallmark of chronic kidney disease, is closely associated with dysregulated gluconeogenesis. Tanshinone I (Tan I), a bioactive compound derived from the traditional Chinese medicine Danshen, exhibits antifibrotic and anti-inflammatory properties. However, its effects on gluconeogenesis and the mechanisms through which it alleviates renal fibrosis remain unclear. This study aimed to investigate whether Tan I promotes gluconeogenesis and mitigates renal fibrosis.

methodsBoth

resultsIn the UUO model, Tan I reduced fibrosis, decreased lactate accumulation, and modulated fibrosis markers while upregulating gluconeogenesis markers. Tanshinone I restored impaired renal gluconeogenesis, as evidenced by increased pyruvate levels.

conclusionsTanshinone I ameliorated renal fibrosis by enhancing gluconeogenesis through upregulation of PGC1α.

Indexed as

Antifibrotic AgentsGluconeogenesisKidney Tubules, ProximalPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRenal Insufficiency, ChronicAbietanesAnimalsCell LineDisease Models, AnimalDrugs, Chinese HerbalFibrosisGlucoseHumansLactic AcidMaleMiceAbietanesAntifibrotic AgentsDrugs, Chinese HerbalGlucoseLactic AcidPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanPpargc1a protein, mousetanshinoneTransforming Growth Factor betachronic kidney diseasegluconeogenesisPGC1αrenal fibrosisTanshinone I

Identifiers

PMID39648664
PMCPMC11632924

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.